1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Wuhan Hiteck Biological Pharma Co.,Ltd

Wuhan Hiteck Biological Pharma Co.,Ltd

300683.SZ
Wuhan Hiteck Biological Pharma Co.,LtdCN flagShenzhen Stock Exchange
25.90
CNY
-1.62
- -
3.39BMarket Cap
Wuhan Hiteck Biological Pharma Co.,Ltd
300683.SZ
(Shenzhen Stock Exchange)

Recent

price

25.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.55
7.94
8.89
9.97
8.69
5.71
6
5.03
5.78
5.4
4.64
4.96
4.14
5.05
Revenue per Share
1.21
1.59
1.09
2.03
1.65
0.91
0.61
-0.24
0.26
-0.11
-0.93
-0.53
-1.77
-0.68
Basic EPS, GAAP
-0.24
1.73
1.91
1.57
0.7
0.34
-0.51
-1.28
-2.21
-0.95
-1.25
-0.16
-0.97
-0.39
Free Cash Flow per Basic Share
0.02
- -
0.61
0.79
- -
0.3
0.2
0.16
- -
0.01
0.02
0.01
0.14
0.14
Dividend per Share
3.22
4.59
4.5
5.68
6.88
6.45
6.86
6.4
6.71
5.49
4.53
3.83
2.06
3.64
Book Value per Share
3.64
7.47
7.55
8.85
18.83
13.33
13.75
12.6
18.21
15.22
14.88
14.28
13.29
14.48
Tangible Book Value per Share
64
69
76
77
86
103
103
104
106
128
130
131
131
127
Basic Weighted Avg Shares
356
549
679
771
750
591
620
524
615
689
602
649
541
639
Sales/Revenue/Turnover
26.62
22.95
22.69
22.68
22.76
19.75
8.79
-3.09
1.37
-0.68
-17.66
-10.47
-22.49
-13.16
Operating Margin (%)
- -
6
7
7
9
14
23
29
38
53
71
92
97
- -
Depreciation Expense
78
110
83
157
142
94
63
-25
28
-14
-121
-69
-231
-86
Net Income, GAAP
14.46
15.19
14.43
14.86
14.86
12.94
15.73
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
21.81
20.03
12.27
20.37
18.98
15.93
10.16
-4.77
4.5
-2.04
-20.06
-10.69
-42.71
-13.41
Profit Margin (%)
180
452
485
570
1,493
1,127
1,083
959
1,333
1,159
1,142
943
921
928
Working Capital
- -
- -
- -
2
2
2
2
5
52
44
37
17
4
24
LT Debt
255
537
597
703
1,643
1,720
1,760
1,725
2,343
2,335
2,496
2,412
2,169
2,364
Total Equity
- -
26.78
23.33
22.82
12.32
6.02
2.64
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
42.05
25.14
38.12
25.98
15.12
9.27
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
41.97
25.21
40.07
27.56
14.94
9.16
-3.64
4
-1.98
-18.76
-12.74
-60.01
-16.72
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
30
17
17
LT Borrowings
12
21
20
LT Finance Leases
5
5
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
131
131
131
Market Capitalization
3,034
2,901
3,255

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,306
1,199
1,167
Cash, Cash Equivalents & STI
869
754
732
Accounts Receivable, Net
62
57
68
Inventories
109
110
99
Total Current Liabilities
363
252
239
Payables & Accruals
- -
- -
- -
ST Debt
30
17
17
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.54%
5.79%
-10.04%
Free Cash Flow
28.59%
99.49%
523.09%
Net Income, GAAP
46.33%
118.17%
233.48%
Sales/Revenue/Turnover
-1.3%
1.59%
-16.57%
Total Cash Common Dividend
- -
583.84%
914.58%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
132
153
166
198
649
2025
157
118
120
- -
541
2026
159
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.13
- -
- -
- -
-0.53
2025
-0.11
- -
- -
- -
-1.77
2026
-0.18
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
0.14
- -
- -
- -
0.14
2026
- -
- -
- -
- -
- -
Similar Companies
The Green Organic Dutchman Holdings Ltd. (TGODD)
Fagron N.V. (ARSUF)
DIOD Maker of Eco-Friendly Equipment and Nutrition Public Joint Stock Company (DIOD.ME)
Allergy Therapeutics plc (AGY.L)
Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ)
Aequus Pharmaceuticals Inc. (AQS.V)
Business
Wuhan Hiteck Biological Pharma Co.,Ltd operates as a biopharmaceutical enterprise, dedicated to the innovation, production, and distribution of a diverse portfolio of pharmaceutical products and services across China. The company's core offerings encompass a range of bioengineered preparations and lyophilized injectable medications, including therapies like Jinlujie, a mouse nerve growth factor for injection, alongside chemical drugs such as omeprazole sodium for injection, cyclic adenosine phosphate, and specialized formulations like Xinye acyclovir dispensable tablets. Their product lineup further extends to targeted treatments like Bingbing Horse & Dragon indomethacin furazolidone suppositories, Xunkeyuan tinidazole suppositories, and Shufu nimodipine sustained-release tablets. Beyond therapeutics, Wuhan Hiteck Biological Pharma also delivers essential diagnostic reagents, including kits for detecting measles and rubella virus nucleic acid, mycoplasma isolation and identification kits, and rapid bacterial vaginosis and coronavirus N-protein detection solutions. The firm also provides active pharmaceutical ingredients (APIs), such as Lopinavir and Ritonavir, in addition to pharmaceutical intermediates. Furthermore, it supports the broader pharmaceutical industry with contract research, manufacturing, and development services for both finished preparations and active pharmaceutical ingredients. The company primarily focuses on the nervous system and oncology therapeutic areas. Established in 1992, Wuhan Hiteck Biological Pharma is headquartered in Wuhan, China, and was publicly listed on the Shenzhen Stock Exchange GEM in 2017. In late 2025, the company announced its intention to pursue a Hong Kong listing.